All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
In January 2018, Mohamad Bassam Sonbol from the Hematology and Oncology Division of Mayo Clinic, Phoenix, AZ, and colleagues, investigated the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) treatment against low-grade non-Hodgkin lymphoma (NHL), in a phase II study (NCT00711828), published ahead of print in Leukemia & Lymphoma.
Rituximab alone has proved to be a successful first-line treatment against indolent mature B-cell lymphoma (NCT00112931), nevertheless disease progression and relapse, following rituximab, still occur in a patient fraction. The aim of this study was to assess whether a combined drug regiment (R-CyBorD) benefits relapsed or refractory patients, with various types of low-grade NHL. The primary endpoint of the study was objective response rate (ORR on assessment), as defined by either a complete response (CR) or a partial response (PR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), duration of response (DOR) and safety, following administration of R-CyBorD.
The results from this phase II trial suggested that the combined use of rituximab with cyclophosphamide, bortezomib and dexamethasone might be effective in only certain NHL subtypes. In support of this, patients with relapsed or refractory FL had a higher response rate from R-CyBorD treatment (ORR = 88%) than MCL patients (ORR = 25%). Along with the differential effect of R-CyBorD on NHL subtypes, drug toxicity should also be taken into careful consideration. Although manageable, Grade ≥ 3 AEs were observed in a considerable number of patients (67%) and were mainly of a hematologic phenotype. A main limitation of the study, mentioned by the authors, was that the overall sample size was small and because of this, so was the sample size within the NHL subtypes. The authors hope that with further larger randomized trials, R-CyBorD could be a potential treatment option for relapsing patients with FL or LPL/WM.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox